Affiliation:
1. Laboratory of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China
Abstract
At present, cancers have been causing deadly fears to humans and previously unpredictable
losses to health. Especially, lung cancer is one of the most common causes of cancer-related mortality
accounting for approximately 15% of all cancer cases worldwide. While Non-Small Cell Lung Carcinomas
(NSCLCs) makes up to 80% of lung cancer cases. The patient compliance has been weakening
because of serious drug resistance and adverse drug effects. Therefore, there is an urgent need for the
development of novel structural agents to inhibit NSCLCs. Nitrogen-containing heterocyclic compounds
exhibit wide range of biological properties, especially antitumor activity. We reviewed some
deadly defects of clinical medicines for the lung cancer therapy and importance of nitrogen based heterocyclic
derivatives against NSCLCs. Nitrogen heterocycles exhibit significant antitumor activity
against NSCLCs. Nitrogen heterocyclic hybrids could be developed as multi-target-directed NSCLC
inhibitors and it is believed that the review is significant for rational designs and new ideas in the development
of nitrogen heterocyclic-based drugs.
Funder
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology,General Medicine
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献